NYXH Market Analysis

Wall Street coverage

third-party context

Wall Street coverage

$8.45median target· current $1.40 (+503.6%)5 analysts

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

News & Sentiment

50 articles · sorted by date
Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Fundamentals

Updated daily after market close
P/E ratio
EPS (TTM)$-2.450.0% YoY
Profit margin0.0%HEALTHCARE
Market cap$140.1MMicro cap

Valuation

Forward P/E
PEG ratio
P/B
3.41
P/S (TTM)
9.14
EV/EBITDA
-2.00

Profitability & growth

ROE (TTM)
-130.0%
Operating margin
-321.7%
Revenue growth YoY
498.9%
Dividend yield
Beta
0.96
Last earnings
May 12, 2026 · Estimate $-0.63 · Reported $-0.43
Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

About Nyxoah

Company profile

Nyxoah is an innovative medical technology firm dedicated to advancing treatment options for obstructive sleep apnea (OSA) through its proprietary Genio system, which employs minimally invasive hypoglossal nerve stimulation. The company is committed to clinical validation and extensive research to enhance patient outcomes and quality of life for individuals affected by OSA. By prioritizing innovation in the sleep medicine domain and fostering strategic partnerships, Nyxoah is strategically positioned to leverage the growing demand for effective OSA treatments, indicating strong prospects for…

Classification

Exchange
NASDAQ
Country
USA
Currency
USD

Company profile

HQ
RUE EDOUARD BELIN 12, MONT-SAINT-GUIBERT, BELGIUM
Fiscal year end
December
Latest quarter
Mar 31, 2026
Market cap$140.1M
Shares outstanding$100.1M
52W high$8.59
52W low$1.26

We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer